Inimmune Corporation

CompanyUnited States

Inimmune Corporation develops one asset, in phase 1 (INI-4001 in advanced solid tumor). Mostly small molecule acting on TLR7; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1
  • INI-4001

    Activates TLR7 and TLR8 to stimulate cytokine production and antitumor immune responses.

    Phase 1, Small molecule, TLR7, advanced solid tumor

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals2
  • Similar companies6

Intelligence